Single-agent venetoclax showed limited activity in R/R AML [29]; however, in vitro reports demonstrated synergistic activity between venetoclax and FLT3 inhibitors in preclinical models [30,31]. The gene discussed is FLT3; the disease is acute myeloid leukemia.